Table 3.

Expression of activation antigens after pamidronate/IL-2 infusion of patients from cohort B

αβ T cells NK cells γδ T cells
Dose level, IL-2 IU/m2 Patient, n CD69, % mean (range) HLA-DR, % mean (range) CD69+ HLA-DR, n/patients (%) CD69, % mean (range) HLA-DR, % mean (range) CD69+ HLA-DR, n/patients (%) CD69, % mean (range) HLA-DR, % mean (range) CD69+ HLA-DR, n/patients (%)
0.25 × 106 3 3 (−56-71) 10 (0-15) 0/3 (0) 24 (−17-43) 0 (0-123) 0/3 (0) 0 (−23-101) 163 (−7-375) 1/3 (33)
0.5 × 106 3 33 (−23-95) 37 (27-86) 1/3 (33) 0 (−26-81) 0 (0-67) 0/3 (0) 53 (38-167) 400 (0-831) 2/3 (66)
1 × 106 4 62 (3-153) 45 (0-122) 0/4 (0) 23 (18-27) 8 (−38-54) 0/2 (0) 183 (82-426) 322 (0-1253) 3/4 (75)
2 × 106 3 65 (52-98) 60 (19-121) 2/3 (66) 81 (−37-103) 93 (79-291) 2/3 (66) 186 (62-230) 124 (122-571) 3/3 (100)
  • Results represent means of increase of the percentages of positive cells analyzed by double or triple staining (NK cells). CD69 was determined on day 2 or 3 and HLA-DR on day 7 after infusion. For analysis of patients expressing CD69 and HLA-DR, a threshold of 50% positive cells on day 8 was defined.